ResMed is under Algo Engine buy conditions and is now up 84% since being added to our model in October 2018.
RMD delivered a solid earnings result and upgrades to earnings are partially offset by the stronger AUD.
You're not a member! Trial today
RMD is looking to resume share buybacks in 2H21.
We see buying support at $26 and suggest investors look to accumulate the stock.
